Susceptibility to tigecycline of Acinetobacter baumannii strains isolated from intensive care unit patients

Abstract

Background: Infections caused by Acinetobacter baumannii are difficult to cure due to the acquisition of resistance by these bacteria and lead to an increase in the general costs of hospitalization. The aim of this study was to determine tigecycline susceptibility of Acinetobacter baumannii strains isolated from intensive care unit and non-intensive care unit patients with skin and soft tissue infections. Methods: MICs were tested by Etest among 70 Acinetobacter baumannii isolates. Results: The MIC range was from 0.5 to 8.0 mg L -1 . For ESBL-producing Acinetobacter baumannii, as well as for strains without carbapenemases, the highest MIC to tigecycline value was 8.0 mg L -1 . For AmpC-producing Acinetobacter baumannii, the highest MIC to tigecycline value was 6.0 mg L -1 and, for MBL-producing strains, 2.0 mg L -1 . Conclusions:The majority of Acinetobacter baumannii strains isolated from ICU and non-ICU patients demonstrated high values of MIC range, MIC 50 and MIC 90 to tigecycline.

Genomic and Phenotypic Evolution of Tigecycline-Resistant Acinetobacter baumannii in Critically Ill Patients

“…The currently available treatment options for CRAB include minocycline, tigecycline, eravacycline, polymyxins, and cefiderocol ( 3 , 5 – 7 ). The emergence of pandrug-resistant A. baumannii worldwide clearly demonstrates the impact of emerging resistance to last-resort antimicrobials (such as tigecycline and polymyxins) ( 8 ).…”

Genetic relatedness of serial rectal isolates of Acinetobacter baumannii in an adult intensive care unit of a tertiary hospital in Kuwait

“…criteria [24]. Susceptibility to tigecycline was determined according to the criteria of Talaga et al [25]. Susceptibility to colistin was performed by agar dilution method and interpreted by the CLSI criteria [24].…”

Analysis of tigecycline in cerebrospinal fluid and serum of patients with multidrug-resistant acinetobacter baumannii central nervous system infection by HPLC-MS/MS

“…TGC also plays an important role in the treatment of multidrug-resistant strains infection including vancomycin-resistant enterococci, methicillin-resistant staphylo-cocci, and acinetobacter baumannii. Therefore, TGC is considered as a therapeutic option for MDRAB infection [4,5] . TGC has been approved for the treatment of complicated skin and skin-structure infections, complicated intra-abdominal infections and community-acquired pneumonia because of the widely distribution in tissue after intravenous infusion [6] .…”